Charles River Laboratories International, Inc.
CRL · NYSE
12/28/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9,564,901 | $12,110,063 | $11,071,935 | $18,949,397 |
| - Cash | $194,606 | $276,771 | $233,912 | $245,237 |
| + Debt | $2,723,994 | $3,066,381 | $3,097,276 | $3,205,570 |
| Enterprise Value | $12,094,289 | $14,899,673 | $13,935,299 | $21,909,730 |
| Revenue | $4,049,989 | $4,129,409 | $3,976,060 | $3,540,160 |
| % Growth | -1.9% | 3.9% | 12.3% | – |
| Gross Profit | $1,331,821 | $1,502,556 | $1,462,651 | $1,334,638 |
| % Margin | 32.9% | 36.4% | 36.8% | 37.7% |
| EBITDA | $581,143 | $1,032,118 | $986,148 | $820,160 |
| % Margin | 14.3% | 25% | 24.8% | 23.2% |
| Net Income | $10,297 | $474,624 | $486,226 | $390,982 |
| % Margin | 0.3% | 11.5% | 12.2% | 11% |
| EPS Diluted | 0.2 | 9.22 | 9.48 | 7.6 |
| % Growth | -97.8% | -2.7% | 24.7% | – |
| Operating Cash Flow | $734,577 | $683,898 | $619,640 | $760,799 |
| Capital Expenditures | -$232,967 | -$318,528 | -$324,733 | -$228,772 |
| Free Cash Flow | $501,610 | $365,370 | $294,907 | $532,027 |